Skip to Content
Merck

Blood Typing Finished Reagents

Dropper bottles containing Bioscot<sup>®</sup> Blood Typing finished reagents

Finished Reagents

Millipore® portfolio of blood typing reagents are made from human or murine monoclonal antibodies and are formulated in low-protein diluents. These monoclonal reagents offer many advantages over polyclonal-based products.

  • Highly specific – no risk of contaminating antibodies
  • Lot-to-lot consistency
  • Low biohazard risk
  • IgM antibodies allow direct agglutination, react without the need for an indirect antiglobulin test, and can be used to type cells with a positive direct antiglobulin test.

We offer a large portfolio of finished reagents compliant with the requirements of the European Directive 98/79/EC. These reagents are offered in a wide range of commercial options, including bulk, reagents for research use, BIOSCOT®-labelled vials carrying the CE mark or unlabeled vials .

We have many years of experience in aiding customers in the registration of products in other countries, so whether your product is Millipore® labelled or in your own trade dress, we can support you with your product registration.

BIOSCOT® labelled reagents are not available to customers in all geographies.

Bulk reagent, reagent for research and unlabeled vial formats share the same reactivity and attributes as our BIOSCOT® CE marked reagents. Bulk reagent & unlabeled vial formats are for further manufacturing or non-diagnostic use. Reagents labelled for research use are not intended for use in clinical diagnostic applications. Read our Reagent Brochure



Related Resources

Blood Typing Monoclonal Antibodies
Video: Blood Typing Monoclonal Antibodies

Explore our range of monoclonal antibodies in various forms, from standardized intermediates, FFMU, finished reagents in bulk, antibodies and reagents for research use.

Watch Now
OEM Blood Typing Case Study
Case Study: OEM Blood Typing

Increase Market Share by Selecting the Right OEM Partner - The OEM Project Situation: A Blood Typing company was going through the process of expanding its portfolio of blood typing platform assays to further penetrate the market...

Read the Study


Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?